Biomarkers.

Background: The measurement of serum and cerebrospinal fluid (CSF) neurofilaments light chain (NfLs) has been proven promising in differentiating the behavioral variant frontotemporal dementia (bvFTD) from non-neurodegenerative mimics, including primary psychiatric disorders and non-progressive cognitive/behavioral changes. However, studies on this topic are based on clinical diagnosis, which remains challenging and potentially confounded by the overlapping clinical phenotypes. We investigated the role of NfLs in this field by classifying patients based on the presence/absence of pathological longitudinal brain volume changes.

Biomarkers.

Background: In clinical settings, the prognosis of patients with subtle cognitive complaints and no imaging evidence of neurodegeneration is often challenging, especially in conditions unrelated to Alzheimer's Disease (AD). We aimed to identify which baseline indicators can help in the clinical decision-making process of patients with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) without AD pathology, by identifying those with faster brain atrophy for their age.

Method: Young-onset SCD and MCI patients (symptoms ≤65yo) were recruited.

Exposure to Cadmium and Other Trace Elements Among Individuals with Mild Cognitive Impairment.

Background: A limited number of studies have investigated the role of environmental chemicals in the etiology of mild cognitive impairment (MCI). We performed a cross-sectional study of the association between exposure to selected trace elements and the biomarkers of cognitive decline.

Methods: During 2019-2021, we recruited 128 newly diagnosed patients with MCI from two Neurology Clinics in Northern Italy, i.

Light at night exposure and risk of dementia conversion from mild cognitive impairment in a Northern Italy population.

Background: A few studies have suggested that light at night (LAN) exposure, i.e. lighting during night hours, may increase dementia risk.

Comparison of Serum and Cerebrospinal Fluid Neurofilament Light Chain Concentrations Measured by Ella™ and Lumipulse™ in Patients with Cognitive Impairment.

Objective: Neurofilament light chain proteins (NfLs) are considered a promising biomarker of neuroaxonal damage in several neurological diseases. Their measurement in the serum and cerebrospinal fluid (CSF) of patients with dementia may be especially useful. Our aim was to compare the NfL measurement performance of two advanced technologies, specifically the Ella™ microfluidic platform and the Lumipulse™ fully automated system, in patients with cognitive disorders.